Clarunis, University Centre for Gastrointestinal and Liver Disorders, Department of Visceral Surgery, University Hospital of Basel, Basel, Switzerland.
Department of Surgery, Charité University Hospital, Campus Benjamin Franklin, Berlin, Germany.
Acta Oncol. 2021 Jun;60(6):727-734. doi: 10.1080/0284186X.2021.1891280. Epub 2021 Mar 18.
Nestin, a class VI intermediate filament protein of the cytoskeleton, and CD34, a transmembrane phosphoglycoprotein, are markers of progenitor cells. This study aimed to evaluate their expression and clinical significance in colorectal cancer.
A clinically annotated tissue microarray, including 599 patients with colorectal cancer, was analyzed by immunohistochemistry. Furthermore, nestin and CD34 correlations with HIF-1a and a panel of cytokines and chemokines were assessed using quantitative reverse transcription PCR and The Cancer Genome Atlas dataset.
Expression of nestin and CD34 was observed only in the tumor stroma. Patients displaying high expression of nestin and CD34 demonstrated higher rates of T1 and T2 tumors ( = .020), lower vascular invasion ( < .001) and improved 5-year overall survival (65%; 95% CI = 55-73 vs 45%; 95% CI = 37-53) after adjusting for clinicopathological characteristics (HR: 0.67; 95% CI = 0.46-0.96). A moderate to strong correlation ( = 0.37-0.78, < .03) of nestin and CD34 was demonstrated for the following markers; HIF-1α, CD4, CD8, FOXP3, IRF1, GATA3, CCL2, CCL3, CXCL12 and CCL21.
Combined expression of nestin and CD34 expression is associated with better overall survival possibly by modulating a favorable immune response.
巢蛋白（Nestin）是细胞骨架的 VI 类中间丝蛋白，CD34 是一种跨膜磷酸糖蛋白，都是祖细胞的标志物。本研究旨在评估其在结直肠癌中的表达及其临床意义。
采用免疫组织化学法对包含 599 例结直肠癌患者的临床注释组织微阵列进行分析。此外，使用定量逆转录 PCR 和癌症基因组图谱数据集评估巢蛋白和 CD34 与 HIF-1a 及一系列细胞因子和趋化因子的相关性。
仅在肿瘤基质中观察到巢蛋白和 CD34 的表达。巢蛋白和 CD34 高表达的患者 T1 和 T2 肿瘤比例更高（ = .020），血管侵犯率更低（ < .001），5 年总生存率（65%；95%CI = 55-73 比 45%；95%CI = 37-53）更高，在调整了临床病理特征后（HR：0.67；95%CI = 0.46-0.96）。巢蛋白和 CD34 与以下标志物呈中到强相关性（ = 0.37-0.78， < .03）：HIF-1α、CD4、CD8、FOXP3、IRF1、GATA3、CCL2、CCL3、CXCL12 和 CCL21。
巢蛋白和 CD34 表达的联合表达与更好的总生存率相关，可能是通过调节有利的免疫反应。
